PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+10.06%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$3.08B
AUM Growth
+$3.08B
(-0.87%)
Cap. Flow
-$95.9M
Cap. Flow
% of AUM
-3.11%
Top 10 Holdings %
Top 10 Hldgs %
37.15%
Holding
94
New
12
Increased
13
Reduced
16
Closed
15
Top Buys
| 1 |
Erasca
ERAS
|
$98.2M |
| 2 |
Caribou Biosciences
CRBU
|
$88.2M |
| 3 |
Cytokinetics
CYTK
|
$52.6M |
| 4 |
SOPHiA GENETICS
SOPH
|
$35.5M |
| 5 |
AstraZeneca
AZN
|
$34.7M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$166M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$68.5M |
| 3 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$43.5M |
| 4 |
Baxter International
BAX
|
$36.9M |
| 5 |
Guardant Health
GH
|
$36.2M |
Sector Composition
| 1 | Healthcare | 94.98% |
| 2 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $171M | 5.03% | 1,561,290 -26,058 | -2% | -$2.85M |
|
2
Outset Medical
OM
$247M
| $147M | 4.31% | 2,966,712 | – | – |
|
3
Eli Lilly
LLY
$657B
| $121M | 3.57% | 525,455 | – | – |
|
4
Arcus Biosciences
RCUS
$1.13B
| $120M | 3.52% | 3,431,010 -67,250 | -2% | -$2.35M |
|
|
5
Cytokinetics
CYTK
$4.23B
| $113M | 3.32% | 3,159,701 +1,472,689 | +87% | +$52.6M |
|
6
AbbVie
ABBV
$372B
| $98.9M | 2.91% | 916,496 -10,327 | -1% | -$1.11M |
|
|
7
Erasca
ERAS
$445M
| $98.2M | 2.89% | +5,191,405 | New | +$98.2M |
|
8
HCA Healthcare
HCA
$94.5B
| $94.8M | 2.79% | 390,507 | – | – |
|
9
Myriad Genetics
MYGN
$593M
| $92.8M | 2.73% | 2,872,918 -216,234 | -7% | -$6.98M |
|
|
10
Caribou Biosciences
CRBU
$174M
| $88.2M | 2.59% | +4,092,309 | New | +$88.2M |
|
11
IQVIA
IQV
$32.4B
| $85.7M | 2.52% | 357,916 | – | – |
|
12
Avantor
AVTR
$9.18B
| $85.1M | 2.5% | 2,079,657 | – | – |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $82.9M | 2.44% | 864,079 -251,925 | -23% | -$24.2M |
|
14
Universal Health Services
UHS
$11.6B
| $72.1M | 2.12% | 520,786 +33,786 | +7% | +$4.67M |
|
15
McKesson
MCK
$85.4B
| $69.6M | 2.05% | 349,181 -7,050 | -2% | -$1.41M |
|
16
Dynavax Technologies
DVAX
$1.19B
| $63.1M | 1.85% | 3,283,570 +292,800 | +10% | +$5.62M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $61.9M | 1.82% | 364,630 -118,355 | -25% | -$20.1M |
|
18
Centene
CNC
$14.3B
| $61.4M | 1.8% | 984,871 -60,602 | -6% | -$3.78M |
|
19
Edwards Lifesciences
EW
$47.8B
| $58.1M | 1.71% | 513,005 | – | – |
|
20
UnitedHealth
UNH
$281B
| $56.8M | 1.67% | 145,295 | – | – |
|
21
Humana
HUM
$36.5B
| $54.3M | 1.6% | 139,420 -2,986 | -2% | -$1.16M |
|
22
Danaher
DHR
$147B
| $53.5M | 1.57% | 175,690 | – | – |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $53.2M | 1.56% | 300,545 +13,499 | +5% | +$2.39M |
|
24
ICU Medical
ICUI
$3.15B
| $51.5M | 1.51% | 220,587 -35,121 | -14% | -$8.2M |
|
25
Penumbra
PEN
$10.6B
| $47.2M | 1.39% | 177,088 +43,329 | +32% | +$11.5M |
|